Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10377462" target="_blank" >RIV/00216208:11110/18:10377462 - isvavai.cz</a>
Alternative codes found
RIV/68378041:_____/18:00493571 RIV/00216208:11140/18:10377462 RIV/00064190:_____/18:N0000018
Result on the web
<a href="https://doi.org/10.1097/MEG.0000000000001154" target="_blank" >https://doi.org/10.1097/MEG.0000000000001154</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MEG.0000000000001154" target="_blank" >10.1097/MEG.0000000000001154</a>
Alternative languages
Result language
angličtina
Original language name
Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy
Original language description
Background: NLRC5 is an interferon [gamma]-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival. Objective: We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients. Patients and methods: We carried out a case-only study in a Czech population of 589 cases; 232 received 5-FU-based therapy. Eleven variants within NLRC5 were selected using in-silico tools. Associations between polymorphisms and survival were assessed by Cox regression analysis adjusting for age at diagnosis, sex, and TNM stage. Survival curves were derived using the Kaplan-Meier method. Results: Two variants showed a significant association with survival. All patients and metastasis-free patients at the time of diagnosis (pM0) who were homozygous carriers of the minor allele of rs27194 had a decreased overall survival (OSall and OSpM0) and event-free survival (EFSpM0) under a recessive model (OSall P=0.003, OSpM0 P=0.005, EFSpM0 P=0.01, respectively). OS was also decreased for all patients and for pM0 patients who carried at least one minor allele of rs289747 (OSall P=0.03 and OSpM0 P=0.003, respectively). Among CRC patients, who underwent a 5-FU-based adjuvant regimen, rs12445252 was associated with OSall, OSpM0 and EFSpM0, according to the dosage of the minor allele T (OSall P=0.0004, OSpM0 P=0.0001, EFSpM0 P=0.008, respectively). Conclusion: Our results showed that polymorphisms in NLRC5 may be used as prognostic markers of survival of CRC patients, as well as for survival in response to 5-FU treatment.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30219 - Gastroenterology and hepatology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Gastroenterology & Hepatology
ISSN
0954-691X
e-ISSN
—
Volume of the periodical
30
Issue of the periodical within the volume
8
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
838-842
UT code for WoS article
000438533500005
EID of the result in the Scopus database
2-s2.0-85050020704